glp-1 drugs heart failure The cardiovascular effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Glucagon-like peptide 1 receptor agonists:
Description
Credits: istock.org
Antiamyloid therapies have recently changed the treatment landscape
New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.
Learn how weight loss drug coverage is changing for Medicare GLP-1 prescriptions in 2026 and how Absolute Best Insurance can help review options.
Here's what clinicians should know.
For individuals of Asian descent, a BMI Current Strategies in Managing Obesity Read More
